Gossamer Bio (NASDAQ:GOSS – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares Gossamer Bio and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gossamer Bio | -235.00% | N/A | -112.04% |
| Aclaris Therapeutics | -921.50% | -61.65% | -42.41% |
Valuation and Earnings
This table compares Gossamer Bio and Aclaris Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gossamer Bio | $48.47 million | 1.32 | -$170.37 million | ($56.00) | -0.19 |
| Aclaris Therapeutics | $7.83 million | 67.36 | -$64.92 million | ($0.58) | -6.50 |
Aclaris Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Gossamer Bio has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Gossamer Bio and Aclaris Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gossamer Bio | 2 | 3 | 5 | 0 | 2.30 |
| Aclaris Therapeutics | 1 | 0 | 5 | 3 | 3.11 |
Gossamer Bio presently has a consensus target price of $256.00, suggesting a potential upside of 2,349.76%. Aclaris Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 191.62%. Given Gossamer Bio’s higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Aclaris Therapeutics.
Insider & Institutional Ownership
81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Aclaris Therapeutics beats Gossamer Bio on 8 of the 14 factors compared between the two stocks.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
